1. Safety and efficacy of omaveloxolone in patients with mitochondrial myopathy
- Author
-
Fernando Scaglia, Bruce H. Cohen, Zarazuela Zolkipli-Cunningham, Perry B. Shieh, Jerry Vockley, Colin Meyer, Megan O'Grady, Angela Goldsberry, Amel Karaa, Amy Goldstein, Mary Kay Koenig, Karen Lindhardt Madsen, Astrid Emilie Buch, John Vissing, Ronald G. Haller, Marni J. Falk, and Colleen C. Muraresku
- Subjects
Adult ,Male ,0301 basic medicine ,NF-E2-Related Factor 2 ,Anti-Inflammatory Agents ,Placebo ,Article ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Double-Blind Method ,Mitochondrial myopathy ,Randomized controlled trial ,Heart Rate ,law ,Heart rate ,medicine ,Humans ,Lactic Acid ,Lead (electronics) ,Adverse effect ,Exercise ,Omaveloxolone ,Dose-Response Relationship, Drug ,business.industry ,Mitochondrial Myopathies ,Middle Aged ,medicine.disease ,Triterpenes ,Dose–response relationship ,Treatment Outcome ,030104 developmental biology ,Anesthesia ,Exercise Test ,Female ,Neurology (clinical) ,business ,Biomarkers ,030217 neurology & neurosurgery - Abstract
ObjectiveTo investigate the safety and efficacy of escalating doses of the semi-synthetic triterpenoid omaveloxolone in patients with mitochondrial myopathy.MethodsIn cohorts of 8–13, 53 participants were randomized double-blind to 12 weeks of treatment with omaveloxolone 5, 10, 20, 40, 80, or 160 mg, or placebo. Outcome measures were change in peak cycling exercise workload (primary), in 6-minute walk test (6MWT) distance (secondary), and in submaximal exercise heart rate and plasma lactate (exploratory).ResultsNo differences in peak workload or 6MWT were observed at week 12 with omaveloxolone treatment vs placebo for all omaveloxolone dose groups. In contrast, omaveloxolone 160 mg reduced heart rate at week 12 by 12.0 ± 4.6 bpm (SE) during submaximal exercise vs placebo, p = 0.01, and by 8.7 ± 3.5 bpm (SE) vs baseline, p = 0.02. Similarly, blood lactate was 1.4 ± 0.7 mM (SE) lower vs placebo, p = 0.04, and 1.6 ± 0.5 mM (SE) lower vs baseline at week 12, p = 0.003, with omaveloxolone 160 mg treatment. Adverse events were generally mild and infrequent.ConclusionsOmaveloxolone 160 mg was well-tolerated, and did not lead to change in the primary outcome measure, but improved exploratory endpoints lowering heart rate and lactate production during submaximal exercise, consistent with improved mitochondrial function and submaximal exercise tolerance. Therefore, omaveloxolone potentially benefits patients with mitochondrial myopathy, which encourages further investigations of omaveloxolone in this patient group.Clinicaltrials.gov identifierNCT02255422.Classification of evidenceThis study provides Class II evidence that, for patients with mitochondrial myopathy, omaveloxolone compared to placebo did not significantly change peak exercise workload.
- Published
- 2020
- Full Text
- View/download PDF